PhotonPharma is advancing the field of cancer treatment through its innovative autologous therapy, specifically targeting solid tumor cancers such as ovarian cancer. Their flagship product, Innocell, is designed to utilize the patient's own tumor cells to create a personalized vaccine that aims to enhance the immune response against cancer. By generating replication-incompetent tumor cells that maintain intact protein neo-antigen expression, Innocell presents a comprehensive array of tumor neo-antigens to the immune system. This approach not only activates the patient's immune system to recognize and attack both primary and metastatic tumor cells but also aims to delay disease progression when used in conjunction with existing treatments like chemotherapy, immunotherapy, and surgery.

The Innocell therapy is characterized by its minimal manipulation of the patient's tumor cells, allowing for a streamlined process from tissue collection to administration. This method ensures a short turnaround time, enabling multiple doses from a single preparation without the need for extensive patient preparation or special post-treatment care. Preclinical studies have demonstrated promising results, with treated mice showing significantly reduced tumor burden and increased survival rates in ovarian cancer models. PhotonPharma's commitment to personalized medicine and rapid access to treatment positions Innocell as a potentially effective option for patients battling recurrent epithelial ovarian cancer.

United States

PhotonPharma is an immuno-oncology company with a break-through technology that stimulates a patient's own immune system to seek out and destroy their cancer cells. We have a patent protected process that precisely inactivates DNA/RNA of a patient's own tumor cells while leaving the cells alive with all of unique tumor specific antigen targets (neoantigens) intact. The process is simple, fast and inexpensive. A patient's tumor cells can be extracted, inactivated and administered back on the same day. Efficacy and safety has been demonstrated in a dog trial (companion animals) and in mouse studies.

PhotonPharma

Company Details